当前位置: X-MOL 学术Biologicals › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Prescription-based prevalence of biological therapy in patients with psoriasis, rheumatoid arthritis, and inflammatory bowel diseases.
Biologicals ( IF 1.7 ) Pub Date : 2019-07-18 , DOI: 10.1016/j.biologicals.2019.07.001
Karel Kostev 1 , Meike Madelung 1
Affiliation  

The aim of this study was to determine the proportion of biological prescriptions over time. This study is based on data from IMS® Diagnosis Monitor and included patients who had received a biological drug in dermatology practices due to psoriasis (PSO), gastroenterology practices due to Crohn's disease (CD) or ulcerative colitis (UC), or rheumatology practices due to rheumatoid arthritis (RA) between April 2015 and December 2018. We analyzed 1,748,948 CD/UC-related prescriptions, 3,968,879 RA-related prescriptions, and 7,321,496 PSO-related prescriptions. Of these, 343,263 (19.6%) prescriptions for IBD, 92,343 (16.2%) prescriptions for RA, and 169,573 (6.9%) prescriptions for PSO were for biologicals. The proportion of biologicals has increased continuously over 4 years, namely from 16.3% to 21.3% (p < 0.01) for CD/UC treatment prescribed by gastroenterologists, from 12.4% to 16.0% (p < 0.01) for RA treatment prescribed by rheumatologists, and from 3.2% to 7.7% (p < 0.01) for PSO treatment prescribed by dermatologists. The proportions of biological therapies and their increase over time were age- and sex-dependent. In summary, we were able to show a significant increase in the proportion of biologicals used to treat CD/UC, RA, and PSO over the last four years.



中文翻译:

在牛皮癣,类风湿关节炎和炎症性肠病患者中,基于处方的生物疗法普遍存在。

这项研究的目的是确定生物处方随时间的比例。这项研究是基于IMS的数据®诊断监测仪,包括在2015年4月之间因牛皮癣(PSO),克罗恩病(CD)或溃疡性结肠炎(UC)引起的皮肤病学实践,类风湿性关节炎(RA)的皮肤病学实践或生物风湿病实践的患者和2018年12月。我们分析了1,748,948例CD / UC相关处方,3,968,879例RA相关处方和7,321,496例PSO相关处方。其中,IBD处方为343,263(19.6%),RA处方为92,343(16.2%),PSO处方为169,573(6.9%)用于生物学。在过去的4年中,生物制剂的比例持续增加,对于胃肠病医生规定的CD / UC治疗,其从16.3%增加到21.3%(p <0.01),对于风湿病医生规定的RA治疗,从12.4%增加到16.0%(p <0.01),从3.2%升至7。皮肤科医生规定的PSO治疗为7%(p <0.01)。生物疗法的比例及其随时间的增长取决于年龄和性别。总之,在过去的四年中,我们能够显示出用于治疗CD / UC,RA和PSO的生物制剂的比例显着增加。

更新日期:2019-07-18
down
wechat
bug